Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PBE vs. RYOIX: which is better?

Bottom line

PBE vs RYOIX: the short answer

PBE (Invesco Biotechnology & Genome ETF) and RYOIX (Biotechnology Fund) are quite different portfolios: only about 37% of their top holdings (by weight) are shared.

But RYOIX is far broader, holding 74 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.

PBE is cheaper at 0.59% vs 1.38% — a difference of $79 a year per $10,000 invested.

Over five years, RYOIX returned +4.0% a year vs +3.4% for PBE.

Updated Nov 19, 2026

PBE vs RYOIX side by side

PBERYOIX
TypeETFMutual fund
Fund familyInvescoGuggenheim
CategoryTechnology SectorTechnology Sector
Expense ratio0.59%1.38%
Annual cost per $10k$59$138
10-yr cost on $10k (prospectus)$738$1,709
Max front loadNone—
12b-1 fee—0%
1-yr return+24.7%+30.7%
5-yr return (annualized)+3.4%+4.0%
10-yr return (annualized)+5.2%+5.9%
Best quarter+25.3%+28.3%
Worst quarter−24.3%−22.5%
Net assets (fund)$281.9M$136.8M
Number of holdings3374
Portfolio turnover103%75%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPBERYOIXDifference
2025+24.7%+30.7%−6.0%
2024+1.1%−0.7%+1.8%
2023+3.7%+6.1%−2.4%
2022−10.8%−13.1%+2.3%
2021+1.6%+1.8%−0.2%
2020+25.5%+22.1%+3.4%
2019+18.3%+25.0%−6.8%
2018+0.2%−9.0%+9.2%
2017+22.4%+29.7%−7.3%
2016−23.0%−19.5%−3.5%

Source: Fund prospectus bar charts

Holdings overlap

10 of PBE's top 25 holdings also appear in RYOIX's top 25.

Shared top holdings
HoldingPBERYOIX
Regeneron Pharmaceuticals, Inc.5.47%2.93%
Amgen Inc.5.22%5.05%
Vertex Pharmaceuticals Inc.4.99%4.32%
Biogen Inc.4.79%2.13%
Gilead Sciences, Inc.4.43%4.49%
United Therapeutics Corp.4.08%1.72%
Illumina, Inc.3.51%1.94%
Alnylam Pharmaceuticals, Inc.3.17%2.36%
Incyte Corp.3.06%1.62%
Neurocrine Biosciences, Inc.2.66%1.52%

Source: SEC Form N-PORT

PBE top 10

  1. Invesco Private Prime Fund — 12.89%
  2. Regeneron Pharmaceuticals, Inc. — 5.47%
  3. Amgen Inc. — 5.22%
  4. CareDx, Inc. — 5.04%
  5. Vertex Pharmaceuticals Inc. — 4.99%
  6. Invesco Private Government Fund — 4.97%
  7. Royalty Pharma PLC — 4.94%
  8. Biogen Inc. — 4.79%
  9. Gilead Sciences, Inc. — 4.43%
  10. United Therapeutics Corp. — 4.08%

RYOIX top 10

  1. Abbvie Inc — 8.17%
  2. Amgen Inc — 5.05%
  3. Gilead Sciences Inc — 4.49%
  4. Vertex Pharmaceuticals Inc — 4.32%
  5. Regeneron Pharmaceuticals Inc — 2.93%
  6. Revolution Medicines Inc — 2.48%
  7. Alnylam Pharmaceuticals Inc — 2.36%
  8. Beone Medicines Ltd — 2.17%
  9. Moderna Inc — 2.15%
  10. Biogen Inc — 2.13%

FAQ

What is the difference between PBE and RYOIX?
PBE (Invesco Biotechnology & Genome ETF) and RYOIX (Biotechnology Fund) are quite different portfolios: only about 37% of their top holdings (by weight) are shared. But RYOIX is far broader, holding 74 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
Which is cheaper, PBE or RYOIX?
PBE has the lower expense ratio (0.59%).
Should I own both PBE and RYOIX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.